Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. - Test2 - elhamkhani - TriplyDB

Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins.

Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins.

http://www.wikidata.org/entity/Q34306079

about

Ligand modulation of the Epstein-Barr virus-induced seven-transmembrane receptor EBI2: identification of a potent and efficacious inverse agonist The chemokine receptor CCR1 is constitutively active, which leads to G protein-independent, β-arrestin-mediated internalization The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity Differential modulation of mu- and delta-opioid receptor agonists by endogenous RGS4 protein in SH-SY5Y cells The receptor concept: pharmacology's big idea Some implications of receptor theory for in vivo assessment of agonists, antagonists and inverse agonists A homotropic two-state model and auto-antagonism Enhanced spontaneous activity of the mu opioid receptor by cysteine mutations: characterization of a tool for inverse agonist screening Gaddum Memorial Lecture 2014: receptors as an evolving concept: from switches to biased microprocessors Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications Two distinct conformations of helix 6 observed in antagonist-bound structures of a 1-adrenergic receptor Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonists Real-time analysis of dopamine: antagonist interactions at recombinant human D2long receptor upon modulation of its activation state Constitutive activation of A(3) adenosine receptors by site-directed mutagenesis Ligands for kappa-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library An Anti-Parkinson's Disease Drug via Targeting Adenosine A2A Receptor Enhances Amyloid-β Generation and γ-Secretase Activity Visualization of a functionally enhanced GFP-tagged galanin R2 receptor in PC12 cells: constitutive and ligand-induced internalization Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor.Opioid receptor signalling mechanisms.Salt bridge integrates GPCR activation with protein trafficking Modulation of silent and constitutively active nociceptin/orphanin FQ receptors by potent receptor antagonists and Na+ ions in rat sympathetic neurons.Constitutive activation of the delta opioid receptor by mutations in transmembrane domains III and VII.Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery.The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists.Structure and regulation of opioid receptors.Inverse agonism and its therapeutic significance.Protean agonism at histamine H3 receptors in vitro and in vivo Genetic variations in human G protein-coupled receptors: implications for drug therapy.Drug analysis based on signaling responses to G-protein-coupled receptors.A Pluridimensional View of Biased Agonism.The 5-HT3B subunit confers spontaneous channel opening and altered ligand properties of the 5-HT3 receptor.Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptor Can intellectualism stifle scientific discovery?Analgesic tone conferred by constitutively active mu opioid receptors in mice lacking β-arrestin 2 Ligand-binding domain subregions contributing to bimodal agonism in cyclic nucleotide-gated channels Opioid antagonists differ according to negative intrinsic efficacy in a mouse model of acute dependence Loss of agouti-related peptide does not significantly impact the phenotype of murine POMC deficiency.The role of opioid antagonist efficacy and constitutive opioid receptor activity in the opioid withdrawal syndrome in mice 'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass?

P2860

Q24306565-D7B405F3-4F40-4EC6-ABC5-B53E1DE62A49 Q24337078-D0C5B4E8-34D6-4133-8DD6-AF5A1D208721 Q24647249-F98AC159-A813-47C4-921F-5FF6883EA699 Q24650065-168CF17B-F4E9-4EE6-89A6-14DE5514AE92 Q24670242-6867520E-B89C-44A5-8905-D41FA4E58E01 Q24671847-72CCB3F5-4A58-43E6-AE7D-1817DEF7110B Q24795064-F66302E2-8F21-40E1-AFAE-23BCE93240F4 Q24804972-1875F6AA-7573-4739-8EBD-7CCDDAD8837E Q27005640-58C7F04D-6CA4-4ABF-9F03-112C1E3722B7 Q27027736-03B27228-FA06-4627-88C2-B476C341E83B Q27667675-5E7A31E8-6312-4D03-A1D4-474050CB49CB Q28279473-F5CB56DF-4F62-4510-905A-48CEC39B81F8 Q28343629-EFB079F0-2C25-457C-9D06-6177216C613C Q28346724-AA71C31A-8CBF-4BF2-82DB-18E02AE9001E Q28366534-AE271664-4B88-46BA-9CF6-111D9C397D18 Q28372894-0FC1C8A1-7AC2-4B5E-83AB-AFE03DC55B77 Q28553493-FDBCC26E-85F1-4FC9-8B32-F9F2BC443945 Q28575154-7621C51D-CFD5-44FD-8849-39CDF3AF3E6E Q33651029-0D186E59-8B34-4755-AFF6-EB2267A98341 Q33687022-62ABB7C1-C091-482D-9FE3-7A6B39110A13 Q33732720-0A67831A-F671-4FF6-8A18-C3743F799EF5 Q33862053-3535DBC9-F17C-45BC-849A-0753B49FF473 Q33865332-9C45B460-CDB9-4DC9-B842-DBFCA7F67241 Q33898777-E1D39540-270D-4797-8F8F-44057F5F5D48 Q33910425-5B18ABC0-91D7-4394-B70C-0028BC1D105A Q34136307-B487BF9B-EDAD-4346-9303-72076E33A293 Q34226789-D23A79C6-318C-4C89-A566-C4CF7C126950 Q34228615-3F65BC90-9AA7-40E3-B266-878F71520C80 Q34461998-01371245-998F-4A00-A21C-31DCB2A4ECF1 Q34470781-7B8A883E-5329-48B4-AFA6-7647920387B0 Q34540545-FFF2EE3D-516C-40B1-B37A-4EA7F645567D Q34734743-96F6C09B-29F4-4582-A13D-FA75869CD707 Q34770179-1F74FB23-4935-47B6-AB87-F83DBC584D86 Q34932240-A856C581-4DB7-4BF6-AF60-E56C58F83BB6 Q34957285-856CC288-1AD7-4408-94CA-75561D37B889 Q35018179-0F321EE2-A802-4A9A-A5A0-9708869CE7EE Q35049029-D51C1E2A-7578-4C6F-B39A-42B5162C28B5 Q35108528-1BB0E16C-6BEA-4436-8A57-A95003E00C31 Q35165171-E90779FA-4E45-4849-ADFF-FEFDE52063FE Q35210020-03F71A88-D63A-4699-A125-05B945BC50FB

P2860

Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins.

http://www.wikidata.org/entity/Q34306079

description

1989 nî lūn-bûn

@nan

1989 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1989 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

1989年の論文

@ja

1989年論文

@yue

1989年論文

@zh-hant

1989年論文

@zh-hk

1989年論文

@zh-mo

1989年論文

@zh-tw

1989年论文

@wuu

name

Antagonists with negative intr ...... upled to GTP-binding proteins.

@ast

Antagonists with negative intr ...... upled to GTP-binding proteins.

@en

Antagonists with negative intr ...... upled to GTP-binding proteins.

@nl

type

label

Antagonists with negative intr ...... upled to GTP-binding proteins.

@ast

Antagonists with negative intr ...... upled to GTP-binding proteins.

@en

Antagonists with negative intr ...... upled to GTP-binding proteins.

@nl

prefLabel

Antagonists with negative intr ...... upled to GTP-binding proteins.

@ast

Antagonists with negative intr ...... upled to GTP-binding proteins.

@en

Antagonists with negative intr ...... upled to GTP-binding proteins.

@nl

P1433

Q34306079-95C1EF02-E4B1-4AA3-8CEF-1D356F72C14A

P1476

Q34306079-292F52A1-5687-49AB-8C96-7CFB2B1570D9

P2093

Q34306079-4D73B558-44A0-46D9-9AD1-C3E39F7ACABA

Q34306079-5B84F520-5E53-4E5A-BD11-69E333BD550C

P2860

Q34306079-00DEA040-ED01-4887-9F5D-04904B55F41E

Q34306079-0E18F34F-3793-493E-99C3-C35DEAB5BD1C

Q34306079-2A5038B9-A22F-448A-88A2-95767E25FFD1

Q34306079-2DF51BFE-6530-41CE-8CB3-F9F1A8B691DB

Q34306079-2EB5689C-21CD-4624-99E3-4568885C064A

Q34306079-3E88FA68-B864-486F-B2C5-3C1434313497

Q34306079-3FA070C1-6353-45B6-85A8-1FA7AA662E04

Q34306079-41BAA9B2-44B1-442D-A12E-008B30C28E9F

Q34306079-4A20717D-C501-4520-B387-14856FF14D41

Q34306079-5594719F-7821-45E9-A962-ED8129801D23

P304

Q34306079-1670624E-E373-4348-A256-60D5ADEE2D0E

P31

Q34306079-B055F525-66E1-4356-B4B5-7BC1CC68508E

P356

Q34306079-19D87F58-3255-40BD-AD59-0FD1BDB25971

P407

Q34306079-64E0D6D9-0BB5-4EA8-BD6E-E4F721DE292B

P433

Q34306079-DF20FF58-4401-4495-A7FE-53130835AE32

P478

Q34306079-F1CAB4E3-68C3-4534-A769-1780E5893FE0

P577

Q34306079-1F903A2B-1B56-408B-8CFD-F35F435B5C7E

P5875

Q34306079-A7595DB1-2DA1-4EAD-A7C3-D1D6A94E2773

P698

Q34306079-3E6A8BFD-FC41-4E9A-8C7B-6CC62F03CA43

P921

Q34306079-8f9089ed-c87e-4098-81aa-baedef83d2b2

P932

Q34306079-F4E2FA2A-ADC9-4CE6-ACA5-507D1844647D

P356

PNAS.86.19.7321

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Antagonists with negative intr ...... upled to GTP-binding proteins.

@en

P2093

Costa T

http://www.w3.org/2001/XMLSchema#string

Herz A

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand: a versatile computerized approach for characterization of ligand-binding systems

G proteins: transducers of receptor-generated signals

Some quantitative uses of drug antagonists

Reconstitution of rat brain mu opioid receptors with purified guanine nucleotide-binding regulatory proteins, Gi and Go.

Agonist-induced increase in apparent beta-adrenergic receptor size.

Reactive sulfhydryl groups of alpha 39, a guanine nucleotide-binding protein from brain. Location and function.

Roles of G protein subunits in transmembrane signalling.

The role of hormone receptors and GTP-regulatory proteins in membrane transduction.

Purification and characterization of the human platelet alpha 2-adrenergic receptor.

A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor.

P304

7321-7325

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.86.19.7321

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

86

http://www.w3.org/2001/XMLSchema#string

P577

1989-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

20604592

http://www.w3.org/2001/XMLSchema#string

P698

2552439

http://www.w3.org/2001/XMLSchema#string

P921

P932

298053

http://www.w3.org/2001/XMLSchema#string